Agios Pharmaceuticals, Inc. (AGIO)
NASDAQ: AGIO · Real-Time Price · USD
27.47
-0.21 (-0.76%)
Mar 6, 2026, 4:00 PM EST - Market closed
Agios Pharmaceuticals Stock Forecast
Stock Price Forecast
The 8 analysts with 12-month price forecasts for Agios Pharmaceuticals stock have an average target of 37.63, with a low estimate of 25 and a high estimate of 65. The average target predicts an increase of 36.99% from the current stock price of 27.47.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Agios Pharmaceuticals stock from 8 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Oct '25 | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 4 | 4 | 4 | 4 | 4 |
| Buy | 4 | 2 | 1 | 1 | 1 | 1 |
| Hold | 1 | 3 | 3 | 3 | 3 | 3 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 9 | 8 | 8 | 8 | 8 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Citigroup | Citigroup | Strong Buy Maintains $38 → $46 | Strong Buy | Maintains | $38 → $46 | +67.46% | Mar 5, 2026 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $62 → $65 | Strong Buy | Maintains | $62 → $65 | +136.62% | Feb 12, 2026 |
| JP Morgan | JP Morgan | Hold Maintains $20 → $25 | Hold | Maintains | $20 → $25 | -8.99% | Jan 6, 2026 |
| Leerink Partners | Leerink Partners | Buy Maintains $34 → $40 | Buy | Maintains | $34 → $40 | +45.61% | Dec 26, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $48 → $62 | Strong Buy | Maintains | $48 → $62 | +125.70% | Dec 24, 2025 |
Financial Forecast
Revenue This Year
94.92M
from 54.03M
Increased by 75.68%
Revenue Next Year
254.02M
from 94.92M
Increased by 167.63%
EPS This Year
-6.74
from -7.12
EPS Next Year
-5.17
from -6.74
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 122.3M | 352.0M | |||
| Avg | 94.9M | 254.0M | |||
| Low | 65.7M | 156.0M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 126.4% | 270.8% | |||
| Avg | 75.7% | 167.6% | |||
| Low | 21.5% | 64.4% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | -6.34 | -3.44 | |||
| Avg | -6.74 | -5.17 | |||
| Low | -6.83 | -5.98 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.